Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Vanda Pharmaceuticals has signed an exclusive license agreement with Israel's private biotech, pharmaceutical and medical nutrition marketing company- Megapharm, for the commercialization of Fanapt in Israel.
Subscribe to our email newsletter
Under the deal, Megapharm will seek regulatory approval for Fanapt, and Vanda will supply Megapharm with Fanapt drug product for packaging and sale in Israel.
Vanda CEO Mihael Polymeropoulos said they have been active in the CNS field for many years and are happy to have the opportunity to launch an important antipsychotic product, that will strengthen its presence and expand portfolio in this therapeutic area.
”We are proud that Vanda has chosen us to introduce such an important treatment option for patients who suffer from the symptoms of Schizophrenia," Polymeropoulos added.
Vanda Pharmaceuticals is a biopharmaceutical company, that specialises on the development and commercialization of products for central nervous system disorders.